Purple Biotech (PPBT) Cash from Discontinued Operations (2020 - 2021)

Purple Biotech's (PPBT) quarterly Cash from Discontinued Operations came in at 374000.0 in Q4 2021, up 48.41% year-on-year from 251998.14 in Q4 2020, and down 1033.33% on a QoQ basis from 33000.0 in Q3 2021.

Purple Biotech (PPBT) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

Purple Biotech (PPBT) has 2 years of Cash from Discontinued Operations data on file, last reported at 374000.0 in Q4 2021.

  • On a quarterly basis, Cash from Discontinued Operations rose 48.41% year-over-year to 374000.0 in Q4 2021; TTM through Dec 2021 was 538000.0, a N/A change from a year earlier, with the FY2021 full-year figure at 374000.0, down 121.94% from the prior year.
  • Cash from Discontinued Operations for Q4 2021 stood at 374000.0, down from 33000.0 in the prior quarter.
  • Over the last five years, Cash from Discontinued Operations for PPBT reached as high as 24000.0 in Q2 2021 and fell as low as 725000.0 in Q4 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Purple Biotech 1.33 Bn 1.33 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 -374,000.00
Dec 31, 2021 -374,000.00
Sep 30, 2021 -33,000.00
Sep 30, 2021 -33,000.00
Jun 30, 2021 24,000.00
Jun 30, 2021 24,000.00
Mar 31, 2021 -155,000.00
Mar 31, 2021 -155,000.00
Dec 31, 2020 -725,000.00
Dec 31, 2020 -725,000.00